Receipt date: 04/20/2009 10609298 - GAU: 1623

OK TO ENTER: /TM/ (01/05/2010)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla et al. Confirmation No.: 9201

Serial No.: 10/609,298 Art Unit: 1623

Filed: June 27, 2003 Examiner: T. McIntosh III

For: 2' AND 3' NUCLEOSIDE PRODRUGS Attorney Docket No: 11874-016-999

FOR TREATING FLAVIVIRIDAE (CAM: 417451-999016)

INFECTIONS IDX 1017

AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. § 1.312

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The following amendment supplements the amendment filed on January 8, 2009 in response to the Office Action of July 10, 2008. Submitted concurrently herewith is a Petition under 37 C.F. R. § 1.182, along with the petition fee set forth in 37 C.F.R. § 1.17(f).

Pursuant to 37 C.F.R. § 1.312, Applicants respectfully request entry of the following amendments and remarks without withdrawing the application from issue.

Pursuant to 37 C.F.R. § 1.71(g)(2), the processing fee set forth in 37 C.F.R. § 1.17(i) for the amendment to the specification will be paid via EFS Web.

Amendments to the Specification begin on page 2.

Remarks begin on page 3.